Biobot Analytics
Wastewater intelligence platform for public health and life sciences.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- Biobot Analytics, Inc.
- Entity type
- COMPANY
- Founded
- 2017
- Headquarters
- 501 Massachusetts Ave, Cambridge, MA 02139, United States
- Company size
- 10–49
- Market role
- Data Provider / Broker
- Official website
- biobot.io
What Biobot Analytics does
Biobot Analytics operates a B2B software-and-data model. It collects and models wastewater-derived biological signals, packages the resulting intelligence into software platforms and licensed datasets, and sells access to public-sector and enterprise customers. Value is created through proprietary data collection and analytics, with customers using the outputs for surveillance, forecasting, operational planning, research, and clinical trial optimisation.
Category differentiation
Biobot Analytics is not an adtech, martech, or consumer analytics company. It is a B2B health intelligence provider using wastewater data for public health and life sciences decision-making.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Biobot Analytics is a US health data and analytics company focused on wastewater intelligence. Its core offering is a proprietary platform and dataset that converts wastewater sampling into population-level insights on pathogens, substances, and genomic indicators, delivered through dashboards, exports, and APIs. The company serves public health agencies, government bodies, healthcare systems, and pharmaceutical or life sciences organisations that need early detection, forecasting, and geographically granular health monitoring. The business generates revenue through contract-based SaaS access, data licensing, and enterprise or government agreements tied to surveillance coverage, sampling cadence, and access levels. Its value proposition is based on privacy-preserving, aggregated health intelligence derived from wastewater rather than individual patient data, which positions it as an infrastructure layer for public health surveillance, clinical trial planning, and health-related commercial analysis.
Business model & monetisation
Biobot Analytics monetises through recurring SaaS subscriptions, proprietary data licensing, and contract-based government or enterprise agreements. Commercial terms are negotiated rather than openly listed, with pricing likely influenced by geographic coverage, sampling frequency, API or dashboard access, and the scope of data delivered. Public-sector customers appear to buy surveillance access and data feeds, while life sciences customers buy premium analytics, forecasting, and dataset access for research and clinical operations.
- Intelligence platform subscriptions
- Software Subscription
- Government surveillance contracts
- Service Fee
- Dataset licensing
- Pay-per-Use
- API and premium data access
- Pay-per-Use
Products & capabilities
No products with linked sources are available in this view.
Products & market categories
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
No sufficiently sourced and dated signals are available for this view.
Explore company relationships
Questions about Biobot Analytics
What is Biobot Analytics?
Biobot Analytics is a US company that turns wastewater sampling data into population-level health intelligence delivered through software platforms, datasets, and APIs.
Who uses Biobot Analytics?
Its paying customers include public health agencies, government bodies, healthcare systems, pharmaceutical companies, clinical trial teams, and research organisations.
How does Biobot Analytics make money?
It earns revenue from SaaS subscriptions, licensed datasets, API access, and contract-based government or enterprise agreements.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
18 publicly documented primary sources and citations linked across the market graph.
Continue your research on Biobot Analytics
Explorer includes additional company details, a Watchlist for up to 25 companies and your personal Strategic Intelligence Agent. It monitors your market daily and delivers tailored briefings with clear strategic context whenever relevant news occurs.
Free, with no time limit.